A Study of Peginterferon Alfa-2a in Participants With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program
Expanded Access Program of PEGASYS® (Peg Interferon Alpha-2a 40 KD) in Patients With HBeAg-Positive And HBeAg-Negative Chronic Hepatitis B
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Phase
Phase
- Phase 4
Kontakte und Standorte
Studienorte
-
-
-
Auckland, Neuseeland
-
Hamilton, Neuseeland
-
New Plymouth, Neuseeland
-
Riccarton, Christchurch, Neuseeland, 8011
-
Rotorua, Neuseeland
-
Whangarei, Neuseeland
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Non-cirrhotic participants
- Hepatitis B surface antigen (HBsAg) positive for at least 6 months
- Hepatitis B surface antibody (anti-HBs) negative
- Elevated serum alanine aminotransferase (ALT) greater than (>) upper limit of normal (ULN) but less than or equal to (</=) 10 times of ULN
- HBeAg positive participants: HBV DNA > 500,000 copies/mL, HBeAg negative participants: HBV DNA >100,000 copies/mL by polymerase chain reaction (PCR)
- Participants with chronic hepatitis B (CHB) who are treatment-naive
- No previous antiviral treatment with interferon (IFN: standard or pegylated) or with a nucleoside analogue
- For women of childbearing potential: negative urine or serum pregnancy test documented within the 24-hour period prior to the first dose of test drug. Willingness to use reliable contraception during the study and for 3 months after treatment completion
Exclusion Criteria:
- Previous antiviral or IFN-based therapy for CHB before enrolment
- Pregnant or breast feeding women participants
- Evidence of decompensated liver disease
- Co-infection with active hepatitis A, hepatitis C, hepatitis D and/or human immunodeficiency virus (HIV)
- History or other evidence of a medical condition associated with chronic liver disease other than viral hepatitis
- Previous or current hepatocellular carcinoma
- History of or other evidence of bleeding from esophageal varices or other conditions consistent with decompensated liver disease
- Alpha-fetoprotein levels of >100 nanograms (ng)/mL
- Severe psychiatric disease
- History of a severe seizure disorder or current anticonvulsant use
- History of immunologically mediated disease, chronic pulmonary disease associated with functional limitation, severe cardiac disease, major organ transplantation or other evidence of severe illness, malignancy, or any other conditions which would make the participant, in the opinion of the investigator, unsuitable for the study
- Thyroid disease uncontrolled by prescribed medications
- Evidence of severe retinopathy
- Alcohol intake more than 3 standard drinks per day for men and 2 standard drinks per day for women
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: HBeAg Negative Participants
HBeAg negative participants will receive peginterferon alfa-2a 180 micrograms (mcg) subcutaneous (SC) injection once weekly (QW) for 48 weeks followed by a 24 weeks treatment-free follow-up period.
|
180 mcg SC injection QW for 48 weeks.
Andere Namen:
|
|
Experimental: HBeAg Positive Participants
HBeAg Positive participants will receive peginterferon alfa-2a 180 mcg SC injection QW for 48 weeks followed by a 24 weeks treatment-free follow-up period.
|
180 mcg SC injection QW for 48 weeks.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of HBeAg Positive Participants With Hepatitis B Virus-deoxy Ribonucleic Acid (HBV-DNA) Less Than (<) 100,000 Copies Per Milliliter (Copies/mL)
Zeitfenster: End of 24-weeks follow-up (Week 72)
|
HBV-DNA was assessed in plasma samples using quantitative Roche polymerase chain reaction (PCR) or Taqman tests.
|
End of 24-weeks follow-up (Week 72)
|
|
Number of Participants With HBV-DNA <20,000 Copies/mL
Zeitfenster: End of 24-weeks follow-up (Week 72)
|
HBV-DNA was assessed in plasma samples using quantitative Roche PCR or Taqman tests.
|
End of 24-weeks follow-up (Week 72)
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Number of Participants With HBV-DNA <400 Copies/mL
Zeitfenster: Week 48 (end of treatment) and Week 72 (end of follow-up)
|
HBV-DNA was assessed in plasma samples using quantitative Roche PCR or Taqman tests.
|
Week 48 (end of treatment) and Week 72 (end of follow-up)
|
|
Number of Participants With Hepatitis B Surface Antigen (HBsAg) Seroconversion
Zeitfenster: Week 48 (end of treatment) and Week 72 (end of follow-up)
|
HBsAg seroconversion was defined as the absence of HBsAg (a negative result for HBsAg) and the presence of anti-HBs (a positive result for anti-HBs).
Both HBeAg positive and negative participants were HBsAg positive at baseline and absence of HBsAg (seroconversion) was analyzed.
|
Week 48 (end of treatment) and Week 72 (end of follow-up)
|
|
Number of Participants With Normalization of Alanine Aminotransferase (ALT) Level
Zeitfenster: Week 48 (end of treatment) and Week 72 (end of follow-up)
|
ALT is an enzyme found mainly in liver and is measured to check if the liver is damaged or diseased.
In case of liver damage or disease, the liver releases ALT into the blood stream and the ALT level increases.
Normal ALT level = less than upper limit of normal (40 units per liter).
|
Week 48 (end of treatment) and Week 72 (end of follow-up)
|
|
Number of Participants With HBeAg Seroconversion
Zeitfenster: Week 48 (end of treatment) and Week 72 (end of follow-up)
|
HBeAg seroconversion for HBeAg positive participants was defined as the loss of HBeAg (a negative result for HBeAg) and the presence of anti-HBe (a positive result for anti-HBe).
|
Week 48 (end of treatment) and Week 72 (end of follow-up)
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Studienbeginn
Primärer Abschluss (Tatsächlich)
Primärer Abschluss
Studienabschluss (Tatsächlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des Verdauungssystems
- RNA-Virusinfektionen
- Viruserkrankungen
- Infektionen
- Durch Blut übertragene Infektionen
- Übertragbare Krankheiten
- Leberkrankheiten
- Hepatitis, viral, menschlich
- Hepadnaviridae-Infektionen
- DNA-Virusinfektionen
- Enterovirus-Infektionen
- Picornaviridae-Infektionen
- Hepatitis, chronisch
- Hepatitis B
- Hepatitis
- Hepatitis A
- Hepatitis B, chronisch
- Antiinfektiva
- Antivirale Mittel
- Peginterferon alfa-2a
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- ML19295
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .